[go: up one dir, main page]

PE20001284A1 - Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migrana - Google Patents

Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migrana

Info

Publication number
PE20001284A1
PE20001284A1 PE1999001083A PE00108399A PE20001284A1 PE 20001284 A1 PE20001284 A1 PE 20001284A1 PE 1999001083 A PE1999001083 A PE 1999001083A PE 00108399 A PE00108399 A PE 00108399A PE 20001284 A1 PE20001284 A1 PE 20001284A1
Authority
PE
Peru
Prior art keywords
migrana
treatment
methoclopramide
receptor agonists
composition
Prior art date
Application number
PE1999001083A
Other languages
English (en)
Inventor
George Harry Sands
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of PE20001284A1 publication Critical patent/PE20001284A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4196—1,2,4-Triazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

SE REFIERE A UNA COMPOSICION QUE COMPRENDE: a)DE 5mg A 125mg DE METOCLOPRAMIDA; b)DE 1mg A 400mg DE UN AGONISTA DE RECEPTORES 5-HT1 TAL COMO ELETRIPTAN, RIZATRIPTAN, SUMATRIPTAN Y NARATRIPTAN, EXCEPTO ZOLMITRIPTAN; c)UN VEHICULO FARMACEUTICAMENTE ACEPTABLE. LA COMPOSICION ES UTIL PARA EL TRATAMIENTO DE LA MIGRANA
PE1999001083A 1998-10-30 1999-10-29 Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migrana PE20001284A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10632898P 1998-10-30 1998-10-30

Publications (1)

Publication Number Publication Date
PE20001284A1 true PE20001284A1 (es) 2000-11-22

Family

ID=22310818

Family Applications (1)

Application Number Title Priority Date Filing Date
PE1999001083A PE20001284A1 (es) 1998-10-30 1999-10-29 Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migrana

Country Status (34)

Country Link
US (2) US6255334B1 (es)
EP (1) EP1126840A1 (es)
JP (1) JP2002528497A (es)
KR (1) KR20010089363A (es)
CN (1) CN1325304A (es)
AP (1) AP2001002129A0 (es)
AR (1) AR019246A1 (es)
AU (1) AU5994799A (es)
BG (1) BG105534A (es)
BR (1) BR9914901A (es)
CA (1) CA2348543A1 (es)
CO (1) CO4950530A1 (es)
CZ (1) CZ20011468A3 (es)
EA (1) EA200100284A1 (es)
EE (1) EE200100243A (es)
GT (1) GT199900189A (es)
HK (1) HK1040929A1 (es)
HR (1) HRP20010298A2 (es)
HU (1) HUP0104696A3 (es)
ID (1) ID28291A (es)
IL (1) IL141957A0 (es)
IS (1) IS5898A (es)
MA (1) MA26702A1 (es)
NO (1) NO20012013D0 (es)
OA (1) OA11669A (es)
PA (1) PA8484801A1 (es)
PE (1) PE20001284A1 (es)
PL (1) PL347541A1 (es)
SK (1) SK5522001A3 (es)
TN (1) TNSN99203A1 (es)
TR (1) TR200101174T2 (es)
TW (1) TW524692B (es)
WO (1) WO2000025778A1 (es)
ZA (1) ZA200103322B (es)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0105131D0 (en) * 2001-03-01 2001-04-18 Pfizer Ltd Compositions having improved bioavailability
US6579898B2 (en) * 2001-03-01 2003-06-17 Pfizer Inc. Compositions having improved bioavailability
US20070122353A1 (en) 2001-05-24 2007-05-31 Hale Ron L Drug condensation aerosols and kits
US6759029B2 (en) * 2001-05-24 2004-07-06 Alexza Molecular Delivery Corporation Delivery of rizatriptan and zolmitriptan through an inhalation route
US7766013B2 (en) 2001-06-05 2010-08-03 Alexza Pharmaceuticals, Inc. Aerosol generating method and device
US7090830B2 (en) 2001-05-24 2006-08-15 Alexza Pharmaceuticals, Inc. Drug condensation aerosols and kits
US7458374B2 (en) 2002-05-13 2008-12-02 Alexza Pharmaceuticals, Inc. Method and apparatus for vaporizing a compound
US7498019B2 (en) 2001-05-24 2009-03-03 Alexza Pharmaceuticals, Inc. Delivery of compounds for the treatment of headache through an inhalation route
US7645442B2 (en) 2001-05-24 2010-01-12 Alexza Pharmaceuticals, Inc. Rapid-heating drug delivery article and method of use
US7585493B2 (en) 2001-05-24 2009-09-08 Alexza Pharmaceuticals, Inc. Thin-film drug delivery article and method of use
CA2446904A1 (en) 2001-05-24 2003-04-03 Alexza Molecular Delivery Corporation Delivery of drug esters through an inhalation route
ATE415155T1 (de) * 2001-05-24 2008-12-15 Alexza Pharmaceuticals Inc Verabreichung von alprazolam, estazolam, midazolam oder triazolam durch inhalation
WO2003041693A1 (en) * 2001-11-09 2003-05-22 Alexza Molecular Delivery Corporation Delivery of diazepam through an inhalation route
WO2003057188A1 (en) 2001-11-21 2003-07-17 Alexza Molecular Delivery Corporation Delivery of caffeine through an inhalation route
WO2003094900A1 (en) 2002-05-13 2003-11-20 Alexza Molecular Delivery Corporation Delivery of drug amines through an inhalation route
EP1567164B1 (en) 2002-11-26 2009-01-14 Alexza Pharmaceuticals, Inc. Use of loxapine for the manufacture of a medicament for the treatment of pain
US20040105818A1 (en) 2002-11-26 2004-06-03 Alexza Molecular Delivery Corporation Diuretic aerosols and methods of making and using them
US7550133B2 (en) 2002-11-26 2009-06-23 Alexza Pharmaceuticals, Inc. Respiratory drug condensation aerosols and methods of making and using them
US7913688B2 (en) 2002-11-27 2011-03-29 Alexza Pharmaceuticals, Inc. Inhalation device for producing a drug aerosol
WO2004104493A2 (en) 2003-05-21 2004-12-02 Alexza Pharmaceuticals, Inc. Methods of controlling uniformity of substrate temperature and self-contained heating unit and drug-supply unit employing same
US7540286B2 (en) 2004-06-03 2009-06-02 Alexza Pharmaceuticals, Inc. Multiple dose condensation aerosol devices and methods of forming condensation aerosols
US20060002989A1 (en) * 2004-06-10 2006-01-05 Ahmed Salah U Formulations of sumatriptan for absorption across biological membranes, and methods of making and using the same
US20050282879A1 (en) * 2004-06-17 2005-12-22 Foad Salehani Methods and composition for treatment of migraine and symptoms thereof
CA2576961A1 (en) 2004-08-12 2006-03-02 Alexza Pharmaceuticals, Inc. Aerosol drug delivery device incorporating percussively activated heat packages
EP1883451B9 (en) 2005-04-13 2011-02-09 Neuraxon Inc. Substituted indole compounds having nos inhibitory activity
WO2007118314A1 (en) * 2006-04-13 2007-10-25 Neuraxon, Inc. 1,5 and 3,6- substituted indole compounds having nos inhibitory activity
US20080139510A1 (en) * 2006-12-07 2008-06-12 Abe Rose Treatment of migraine headaches with sublingual amino acids
EP2121088B1 (en) 2007-03-09 2016-07-13 Alexza Pharmaceuticals, Inc. Heating unit for use in a drug delivery device
CA2705835A1 (en) * 2007-11-16 2009-05-22 Neuraxon, Inc. Indole compounds and methods for treating visceral pain
CA2705422A1 (en) * 2007-11-16 2009-05-22 The Arizona Board Of Regents On Behalf Of The University Of Arizona Methods for treating visceral pain
CA2705833A1 (en) * 2007-11-16 2009-05-22 Subhash C. Annedi 3,5-substituted indole compounds having nos and norepinephrine reuptake inhibitory activity
AU2013202680C1 (en) * 2008-04-28 2016-06-23 Zogenix, Inc. Novel formulations for treatment of migraine
WO2019152873A1 (en) 2018-02-02 2019-08-08 Alexza Pharmaceuticals, Inc. Electrical condensation aerosol device

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5698571A (en) * 1994-10-05 1997-12-16 Eli Lilly And Company 5-HT1F mediated inhibition of neurogenic meningeal extravasation: a method for the treatment of migraine
IL127955A0 (en) * 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
GB9709739D0 (en) 1997-05-14 1997-07-02 Merck Sharp & Dohme Pharmaceutical formulation

Also Published As

Publication number Publication date
CO4950530A1 (es) 2000-09-01
TW524692B (en) 2003-03-21
US20010020036A1 (en) 2001-09-06
AR019246A1 (es) 2001-12-26
PA8484801A1 (es) 2000-09-29
US6255334B1 (en) 2001-07-03
IS5898A (is) 2001-03-16
EP1126840A1 (en) 2001-08-29
NO20012013L (no) 2001-04-24
TNSN99203A1 (fr) 2005-11-10
AP2001002129A0 (en) 2001-06-30
TR200101174T2 (tr) 2001-10-22
OA11669A (en) 2005-01-05
BR9914901A (pt) 2001-07-17
KR20010089363A (ko) 2001-10-06
ID28291A (id) 2001-05-10
JP2002528497A (ja) 2002-09-03
WO2000025778A1 (en) 2000-05-11
CN1325304A (zh) 2001-12-05
HUP0104696A3 (en) 2003-05-28
CZ20011468A3 (cs) 2002-04-17
HK1040929A1 (zh) 2002-06-28
ZA200103322B (en) 2002-06-10
IL141957A0 (en) 2002-03-10
GT199900189A (es) 2001-04-21
CA2348543A1 (en) 2000-05-11
NO20012013D0 (no) 2001-04-24
SK5522001A3 (en) 2002-05-09
MA26702A1 (fr) 2004-12-20
HRP20010298A2 (en) 2002-06-30
EE200100243A (et) 2002-12-16
EA200100284A1 (ru) 2001-10-22
PL347541A1 (en) 2002-04-08
BG105534A (en) 2001-12-29
HUP0104696A2 (hu) 2002-05-29
AU5994799A (en) 2000-05-22

Similar Documents

Publication Publication Date Title
PE20001284A1 (es) Agonistas de receptores 5-ht1 y metoclopramida para el tratamiento de la migrana
FI910228A0 (fi) Heteroaromatiska foereningar med fem ringatomer och substituerade med indol.
BR9406481A (pt) Derivados de indol como agonistas do tipo 5-HT1 para utilização na enxaqueca
PE20010817A1 (es) Compuestos para el tratamiento de la disfuncion sexual femenina
PT1305286E (pt) Ciclopentanoindoles composicoes que contem os referidos compostos e metodos de tratamento
GT199700009AA (es) Terapia combinada para la osteoporosis
RU2008143545A (ru) Применение антагониста рецептора ат-1 или модулятора рецептора ат-2 для лечения болезней, связанных с увеличением содержания рецепторов ат-1 или ат-2
EA200100519A1 (ru) Композиции на основе тонкоизмельченного эплеренона
AR021981A1 (es) Composicion farmaceutica para una administracion por via oral destinada a evitar la desviacion de uso en detrimento de un tercero
UY25078A1 (es) Composiciones farmacéuticas que contienen eletriptan hemisulfato estabilizadas con cafeína
BR0005765A (pt) Combinação de inibidores de aldose redutase e agentes anti-hipertensivos para o tratamento de complicações diabéticas
AR025883A1 (es) Utilizacion de antagonistas de los receptores de los cannabinoides centrales para la preparacion de medicamentos
SG188700A1 (en) Use of at-1 receptor antagonist or at-2 receptor modulator for treating diseases associated with an increase of at-1 or at-2 receptors
EA199901114A1 (ru) Полиморфная форма 2-(r)-(1-(r)-(3,5-бис(трифторметил)фенил)этокси)-3-(s)-(4-фтор)фенил-4-(3-(5-оксо-1h,4h-1,2,4-триазоло)метилморфолина в качестве антагониста рецептора тахикина
NO20011440D0 (no) mGluR5-antagonister for behandling av smerte og angst
MX9304595A (es) Derivados de 1,2,4-triazola substituidos en 4
ES2163085T3 (es) Utilizacion de un extracto de cimicifuga racemosa.
EA200100089A1 (ru) Предотвращение рецидива мигрени
FI955260A0 (fi) Transdermaalisia terapeuttisia systeemejä serotoniiniagonistien antamista varten
DE69819742D1 (de) Indolderivate als 5-ht1b und 5-ht1d agonisten
EA199901116A1 (ru) Композиция, включающая 5-[4-[2-(n-метил-n-2-пиридил)-амино)этокси]бензил]тиазолидин-2,4-дион
PE20020557A1 (es) Uso de agonistas selectivos del receptor de dopamina d4 para tratar la disfuncion sexual
PE20010123A1 (es) Agonistas del receptor 5ht1 y un inhibidor de la cox-2 o un aine para el tratamiento de la migrana
CO5251423A1 (es) Tratamiento de endometriosis o infertilidad, o mejora de la fertilidad
IT1270612B (it) Derivati eterociclo-condensatori di morfinoidi

Legal Events

Date Code Title Description
FC Refusal